Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
70,06 USD | -1,32% | -3,38% | -1,89% |
Omzet 2024 * | 137 mln. 128 mln. | Omzet 2025 * | 158 mln. 147 mln. | Marktkapitalisatie | 1,26 mld. 1,17 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 28 mln. 26,14 mln. | Nettowinst (verlies) 2025 * | 52 mln. 48,54 mln. | EV/omzet 2024 * | 9,15 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 7,97 x |
K/w-verhouding 2024 * |
42,4
x | K/w-verhouding 2025 * |
24,8
x | Werknemers | 58 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 94,07% |
Recentste transcriptie over Ligand Pharmaceuticals Incorporated
1 dag | -1,32% | ||
1 week | -3,38% | ||
Lopende maand | -4,15% | ||
1 maand | +1,18% | ||
3 maanden | -6,93% | ||
6 maanden | +39,33% | ||
Lopend jaar | -1,89% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 01-03-07 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 01-11-22 |
President | 49 | 06-08-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John W. Kozarich
CHM | Chairman | 74 | 01-03-03 |
John LaMattina
BRD | Director/Board Member | 74 | 01-02-11 |
Stephen Sabba
BRD | Director/Board Member | 64 | 04-08-08 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.24% | 27 M€ | -5,68% | - | |
0.14% | 0 M€ | 0,00% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
25-04-24 | 70,07 | -1,31% | 11 611 |
24-04-24 | 71 | +1,59% | 152 962 |
23-04-24 | 69,89 | +1,98% | 140 672 |
22-04-24 | 68,53 | -5,44% | 247 324 |
19-04-24 | 72,47 | -0,07% | 137 196 |
uitgestelde koers Nasdaq, 25 april 2024 om 16:43 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,89% | 1,26 mld. | |
+23,76% | 562 mld. | |
-6,56% | 358 mld. | |
+18,53% | 322 mld. | |
+7,35% | 297 mld. | |
+12,58% | 219 mld. | |
+5,93% | 199 mld. | |
-10,39% | 196 mld. | |
-11,03% | 149 mld. | |
-6,83% | 146 mld. |